A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05633355
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
187
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Rocatinlimab
Sponsor
Amgen